The combined analysis of p14ARF/p15INK4b/p16INK4a may in the future be used as prognostic marker for patients with vulvar carcinomas, but future studies must be performed to eventually confirm a role for these INK4 proteins as predictor for therapy. Here, CDKN2A is linked to vulvar carcinoma.